Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Growth hormone subnormality in Down syndrome

L Ragusa, C Romano, P Failla

    American Journal of Medical Genetics
    |July 15, 1992
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Corrigendum to "Cost-effectiveness of first-line osimertinib informed by electronic medical records via text-mining: a real-world Italian case study of <i>EGFR</i>-mutated advanced NSCLC patients": [ESMO Real World Data and Digital Oncology Volume 10, December 2025, 100198].

    ESMO real world data and digital oncology·2026
    Same author

    Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records.

    ESMO real world data and digital oncology·2026
    Same author

    Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies.

    Cancer treatment reviews·2025
    Same author

    Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025
    Same author

    Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO).

    ESMO open·2024
    Same author

    Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671).

    Annals of oncology : official journal of the European Society for Medical Oncology·2024